© 2005 European Society for Medical Oncology
Invited Paper |
Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer
1 Clinical Experimental Oncology Laboratory, 2 Histopathology Service, 3 Medical Oncology Unit, 4 Women's Department, National Cancer Institute, via Amendola 209, 70125 Bari, Italy
* Correspondence to: Dr Angelo Paradiso, Clinical Experimental Oncology Laboratory, National Cancer Institute, Via Amendola 209, 70126 Bari, Italy. Phone/Fax +39-080-5555561; Email: a.paradiso{at}oncologico.bari.it
Background: Several studies looked for tumor biomarkers predictive for paclitaxel sensitivity but till now no reliable biomarkers are available. The aim of this study was to verify the potential predictive value of ß-tubulin III and IV, vascular endothelial growth factor-receptor (VEGFR-1), HER2/neu and microvessel density (mVD), in a group of 70 patients with advanced breast cancer (ABC) treated with paclitaxel-based chemotherapy.
Patients and methods: Immunohistochemical analysis (ICA) of HER2, VEGFR-1, mVd, ß-tubulin III and ß-tubulin IV expression were performed in a series of 72 advanced breast cancer. Furthermore apoptotic fraction with TUNEL analysis was evaluated.
Results: ß–tubulin III ICA expression was predictive of progression after chemotherapy. In fact only 2% of the patients with low ß-tubulin III expression progressed after paclitaxel chemotherapy vs 38% of those with high ß-tubulin III tumor expression (P=0.000; by 
2). This evidence was confirmed by a logistic regression analysis (OR 28.789; 95% CI 3.212–258,072; P=0.004). There was not a significant association between other biomarkers' characteristics and clinical response to chemotherapy. A Cox multivariate analysis, with overall survival as a dependent variable, showed that only HER2 expression was independently associated (OR 2.39; 95% CI 1.09–5.23; P=0.03) with overall survival.
Conclusions: We suggest that class III ß-tubulin immunohistochemical expression analysis could be a potentially relevant tumor biomarker for paclitaxel resistance in advanced breast cancer patients.
Key words: breast cancer, taxane, predictive factor, tubulin
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Prislei, S. Mozzetti, F. Filippetti, M. De Donato, G. Raspaglio, L. Cicchillitti, G. Scambia, and C. Ferlini From plasma membrane to cytoskeleton: a novel function for semaphorin 6A Mol. Cancer Ther., January 1, 2008; 7(1): 233 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Seve, R. Lai, K. Ding, T. Winton, C. Butts, J. Mackey, C. Dumontet, L. Dabbagh, S. Aviel-Ronen, L. Seymour, et al. Class III {beta}-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10 Clin. Cancer Res., February 1, 2007; 13(3): 994 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ferrandina, G. F. Zannoni, E. Martinelli, A. Paglia, V. Gallotta, S. Mozzetti, G. Scambia, and C. Ferlini Class III {beta}-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients. Clin. Cancer Res., May 1, 2006; 12(9): 2774 - 2779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Seve, J. Mackey, S. Isaac, O. Tredan, P.-J. Souquet, M. Perol, R. Lai, A. Voloch, and C. Dumontet Class III {beta}-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel Mol. Cancer Ther., December 1, 2005; 4(12): 2001 - 2007. [Abstract] [Full Text] [PDF]
|
|